Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nasdaq  >  Celgene Corporation    CELG

Delayed Quote. Delayed  - 10/20 10:14:59 pm
121.33 USD   -10.76%
10/20 SKECHERS : PayPal and Skechers jump while Celgene tumbles
10/20 NASDAQ 100 MOVE : Celg, pypl
10/20 S&P 500 MOVERS : Celg, pypl
SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector newsTweets

Celgene Corporation : Celgene 1st-Quarter Net Down 4.1% Amid Increased Costs

share with twitter share with LinkedIn share with facebook
share via e-mail
0
04/25/2013 | 02:25pm CEST
   By Ben Fox Rubin 
 

Celgene Corp.'s (CELG) first-quarter profit fell 4.1% as the drug maker saw higher expenses offset stronger revenue from its Revlimid and Vidaza drugs.

The company raised its full-year guidance to a range of $5.55 to $5.65 a share in adjusted earnings from $5.50 to $5.60. It also backed its full-year product sales outlook.

Celgene has continued to post improved revenue, with its flagship blood-cancer treatment Revlimid grabbing more market share and sales of Vidaza, a blood-cancer treatment that lost patent exclusivity in May 2011, continuing to rise in the face of generic competition. The biopharmaceutical company also is expanding its core hematology franchise and building out new product lines in cancer and psoriasis as part of a strategy to achieve $12 billion in product sales by 2017.

Celgene reported a profit of $384.9 million, or 89 cents a share, down from $401.5 million, or 90 cents, a year earlier. Excluding items such as stock-based compensation, per-share earnings rose to $1.37 from $1.08.

Revenue grew 15% to $1.46 billion.

Analysts polled by Thomson Reuters had most recently forecast earnings of $1.35 a share on revenue of $1.47 billion.

Total costs and expenses rose 27%.

Revlimid sales were up 16% to $1 billion while Vidaza sales rose 10% to $204 million.

Shares closed Wednesday at $118.28 and were down 0.2% premarket. The stock has gained 51% so far this year.

Write to Ben Fox Rubin at [email protected]

Order free Annual Report for Celgene Corp.

Visit http://djnweurope.ar.wilink.com/?ticker=US1510201049 or call +44 (0)208 391 6028

share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on CELGENE CORPORATION
10/20 SKECHERS : PayPal and Skechers jump while Celgene tumbles
10/20 NASDAQ 100 MOVERS : Celg, pypl
10/20 S&P 500 MOVERS : Celg, pypl
10/19 EVOTEC : Achieves First Milestone in Neurodegeneration Alliance with Celgene
10/19 CELGENE : Patent Issued for Romidepsin Formulations and Uses (USPTO 9782451)
10/19 CELGENE CORPORATION (NASDAQ : CELG) Files An 8-K Costs Associated with Exit or D..
10/19 CELGENE CORP /DE/ : Costs Associated with Exit or Disposal Activities (form 8-K)
10/19DJCELGENE : Halts Crohn's Disease Drug Trials
10/19 CELGENE : Provides Update on GED-0301 (mongersen) Inflammatory Bowel Disease Pro..
10/19 CELGENE : Phase III Efficacy and Safety Data for Oral Ozanimod in Relapsing Mult..
More news
News from SeekingAlpha
10/20 Celgene selloff weighs on biotechs, IBB down 1%
10/20 Midday Gainers / Losers
10/20 YOUR DAILY PHARMA SCOOP : Johnson & Johnson's Mixed Signals, Celgene's Mongersen..
10/20 HEALTHCARE - TOP 5 GAINERS / LOSERS : 00 am
10/20 Analyst weigh in on Celgene's flop in Crohn's with mongersen; shares down 10%
Financials ($)
Sales 2017 13 226 M
EBIT 2017 7 529 M
Net income 2017 4 508 M
Debt 2017 3 949 M
Yield 2017 -
P/E ratio 2017 21,68
P/E ratio 2018 16,66
EV / Sales 2017 7,48x
EV / Sales 2018 6,08x
Capitalization 94 923 M
Chart CELGENE CORPORATION
Duration : Period :
Celgene Corporation Technical Analysis Chart | CELG | US1510201049 | 4-Traders
Technical analysis trends CELGENE CORPORATION
Short TermMid-TermLong Term
TrendsBearishNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 29
Average target price 149 $
Spread / Average Target 22%
EPS Revisions
Managers
NameTitle
Mark J. Alles Chief Executive Officer & Director
Scott Andrew Smith President & Chief Operating Officer
Robert J. Hugin Executive Chairman
Peter N. Kellogg Chief Financial Officer & Executive Vice President
Joseph S. Camardo Senior Vice President-Global Medical Affairs
Sector and Competitors
1st jan.Capitalization (M$)
CELGENE CORPORATION18.51%94 923
JOHNSON & JOHNSON23.29%382 202
NOVARTIS13.50%226 404
PFIZER11.58%216 886
ROCHE HOLDING LTD.5.55%207 116
MERCK AND COMPANY7.88%174 223